PMID- 6314173
OWN - NLM
STAT- MEDLINE
DCOM- 19831220
LR  - 20190511
IS  - 0148-396X (Print)
IS  - 0148-396X (Linking)
VI  - 13
IP  - 4
DP  - 1983 Oct
TI  - Intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and systemic 
      chemotherapy for malignant gliomas: a follow-up study.
PG  - 420-6
AB  - Twenty-five adults who harbored malignant gliomas received 72 courses of 
      intraarterial 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) (100 mg/m2) and 67 
      courses of systemic vincristine (1.0 mg/m2) and procarbazine (100 mg/m2) as 
      induction therapy (BVP) followed by 106 courses of systemic 
      1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea (methyl-CCNU) (130 mg/m2), 
      vincristine, and procarbazine as maintenance therapy (MVP). With a 6-week 
      interval between each treatment, the median and range for the number of courses 
      of BVP were 3 and 1 to 4 and those for MVP were 3 and 0 to 14, respectively. 
      Fifteen patients (60%) responded to both BVP and MVP, and 10 (40%) did not. The 
      overall median survival time was 12.7 months (range, 1.8 to 48.5+ months). Two of 
      3 patients who had recurrent gliomas responded and survived for 37+ to 45+ 
      months. Seven of 10 who had nonirradiated glioblastomas responded and survived 
      for 9 to 22 months. Four who had nonirradiated anaplastic astrocytomas all 
      responded and survived for 38+ to 48.5+ months. Two who also received 
      radiotherapy (1 glioblastoma and 1 primitive neuroectodermal tumor) benefited and 
      survived for 16.9 and 28.5+ months. All who did not respond favorably died within 
      8 months. During the infusion of BCNU, complications included transient orbital 
      and head pain, periorbital and scleral erythema in all patients, and a focal 
      seizure in 1 (4%). During the 6-month induction periods, leukopenia and 
      thrombocytopenia occurred in 1 (4%), deep vein thrombosis occurred in 9 (36%), 
      pulmonary emboli occurred in 8 (32%), upper respiratory infections occurred in 6 
      (24%), pneumonia occurred in 9 (36%), and herpes zoster occurred in 1 
      (4%).(ABSTRACT TRUNCATED AT 250 WORDS)
FAU - West, C R
AU  - West CR
FAU - Avellanosa, A M
AU  - Avellanosa AM
FAU - Barua, N R
AU  - Barua NR
FAU - Patel, A
AU  - Patel A
FAU - Hong, C I
AU  - Hong CI
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Neurosurgery
JT  - Neurosurgery
JID - 7802914
RN  - 13909-09-6 (Semustine)
RN  - 35S93Y190K (Procarbazine)
RN  - 5J49Q6B70F (Vincristine)
RN  - U68WG3173Y (Carmustine)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Astrocytoma/drug therapy
MH  - Brain Neoplasms/*drug therapy
MH  - Carmustine/administration & dosage
MH  - Carotid Artery, Internal
MH  - Combined Modality Therapy
MH  - Female
MH  - Glioblastoma/drug therapy
MH  - Glioma/*drug therapy
MH  - Humans
MH  - Infusions, Intra-Arterial
MH  - Male
MH  - Middle Aged
MH  - Procarbazine/administration & dosage
MH  - Prognosis
MH  - Semustine/administration & dosage
MH  - Vincristine/administration & dosage
EDAT- 1983/10/01 00:00
MHDA- 1983/10/01 00:01
CRDT- 1983/10/01 00:00
PHST- 1983/10/01 00:00 [pubmed]
PHST- 1983/10/01 00:01 [medline]
PHST- 1983/10/01 00:00 [entrez]
AID - 10.1227/00006123-198310000-00013 [doi]
PST - ppublish
SO  - Neurosurgery. 1983 Oct;13(4):420-6. doi: 10.1227/00006123-198310000-00013.